Abstract: Objective To examine argatroban in the Prevention of thrombosis of semipermanent double channel catheter in MHD patients,and compare the effect of preventing thrombosis between in using urokinase group，LMWH group and argatroban group,and investigate further the efficacy and safety of argatroban in preventing thrombosis.Methods The 60 patients of semipermanent double channel catheter were collected since Jan.2011 to Dec.2012,including 20 patients using urokinase group , 20 patients using argatroban group and 20 patients the control group using LMWH,and drugs were taken monthly,a total of 12 months. The adverse events of pre-dialysis and intervention,blood flow, transmembrane pressure and venous pressure of dislysis were observed in three groups ,and three groups were controled respectively before and after treatments. The changes of CRP were observed in three groups after treatments.Results Argatroban group, the incidence of complications is 17.5%, urokinase group is 29.16% and the control group is 25.83% ; argatroban group and urokinase group,the adverse events rate before and after treatments are 14.1%vs 4.3%（p<0.05） and 14.2%vs10.3% （p<0.05）, and the control group is 13.8%vs13.2% （p>0.05）, and argatroban group and urokinase group, intervention rate before and after treatments are17.2%vs 4.8%（p<0.05） and 14.2%vs10.3% （p<0.05），the control is and 17.5%vs17.1% （p>0.05）, argatroban group and urokinase group, the blood flow are all increaseed before and after treatments,and transmembrane pressure and venous pressure are all reduced（p<0.05）, while the control（p>0.05）; argatroban group,the CRP gradually is reduced after 12 months treatments（p<0.05）.Conclusion Argatroban or urokinase could prevent the thrombosis of semipermanent double channel catheter,which are dripped at regular period,and the blood flow of dialysis is increased; argatroban group has higher safety,less thrombosis incidence and inflammatory reaction than urokinase group,the long-time argatroban application can reduce inflammatory.

Key words: semipermanent double channel cathete, Thrombosis, Argatoban, Prevention